Life Biosciences launches a Phase I trial for cellular reprogramming to treat age-related macular degeneration, challenging aging norms with FDA’s Plausible Mechanism Pathway, amid rising invest...
The FDA’s updated guidelines on cellular reprogramming, highlighted by Life Biosciences’ ER-100 trial for eye conditions, signal a pivotal shift that could accelerate anti-aging therapies,...
Recent advancements in cellular reprogramming, including significant funding and clinical trials, are transforming anti-aging science by targeting root causes of age-related diseases. Cellular reprogr...
Recent advances in partial cellular reprogramming using OSKM factors show promise in extending healthspan and treating age-related diseases, with biotech firms accelerating towards human trials. New r...
Recent studies show that targeting engrams with partial reprogramming factors improves memory in mouse models, offering a potential therapy for Alzheimer’s and age-related cognitive decline. New...
Life Biosciences receives FDA clearance for the first human trial of cellular reprogramming targeting glaucoma and NAION, signaling regulatory openness to longevity therapies and potential vision rest...
Recent studies show small molecules efficiently mimic Yamanaka factors to reverse epigenetic aging, with clinical trials on the horizon, offering a safer alternative to gene therapies. Advancements in...
